$30.46
-0.96(-3.06%)
Mkt Cap $2.8B
$13.49
$40.28
52-Week Range
At a Glance
AI-generatedTravere Therapeutics reported total revenue of $490.7 million for FY 2025, with a net loss of $25.5 million.
Revenue breakdown: Product (40.9%), FILSPARI (25.8%), Tiopronin Products (15%).
8-K
Travere Therapeutics, Inc. filed an 8-K on February 19, 2026, disclosing results of operations under Item 2.02 with Exhibit 99.1 press release attached. The filing includes references to analyst consensus EPS context for the period.$2.8B
Market Cap
$501M
Revenue
-$51M
Net Income
Employees385
Fundamentals
How The Business Makes Money
Revenue by Segment
Product40.9%($765M)
FILSPARI25.8%($483M)
Tiopronin Products15%($281M)
License11.8%($221M)
Market Access Milestone4.3%($80M)
Regulatory Milestone1.9%($35M)
Royalty0.3%($7M)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001438533
ISINUS89422G1076
CUSIP89422G107
Phone888 969 7879
Address3611 Valley Centre Drive, San Diego, CA, 92130, US
SEC EDGAR